Is retatrutide safe?
Nobody can say yet. A phase 2 trial in 338 people reported a tolerability profile similar in kind to other incretin drugs with a heart-rate signal; phase 3 is what establishes safety and it is not finished.
Back to Research Guide
Tier 1 — Human RCT (Phase 2)
Research Purposes Only
Tier 1 — Human RCT (Phase 2)
Retatrutide
GLP-3 R / GLP-3 RT: Phase 3 Results, Approval Status & Verified Vendor Prices
Retatrutide (LY3437943) — GIP/GLP-1/Glucagon Triple Agonist
Last reviewed: 9 October 2026
Research Purposes Only. Retatrutide is sold by research vendors strictly for qualified laboratory research use only. It is not intended for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic application. Statements on this page have not been evaluated by the FDA.
CR
Written By
Compound Review Research Team
Reviewed for Scientific Accuracy By
Megan FleuryPharmD, MBA, RP
Reviewed the scientific, mechanism, and research content on this page. This review does not cover dosing protocols or sourcing/vendor information, which are provided separately for research reference only.
Reviewed: 9 October 2026
All content is reviewed for scientific accuracy against peer-reviewed literature. View our editorial methodology.
So What Does This Actually Mean?
Plain English summary — no PhD required
GLP-3 R (Retatrutide) is one of the newest and most discussed compounds in metabolic research. It's a triple-receptor agonist — meaning it activates three different hormone receptors simultaneously: GLP-1R, GIP-R, and glucagon receptor. This triple action is what makes it particularly interesting compared to existing GLP-1 drugs like Ozempic, which only target one receptor.
What It Does
By hitting all three receptors at once, Retatrutide combines the appetite-suppressing, insulin-stimulating effects of GLP-1 with the additional metabolic benefits of GIP (which enhances insulin secretion and may improve GLP-1 receptor sensitivity) and glucagon (which increases energy expenditure and fat burning). In Phase 2 clinical trials published in the New England Journal of Medicine in 2023, Retatrutide produced weight loss of up to 24.2% of body weight over 48 weeks — the highest ever reported for a pharmacological agent in a clinical trial.
Why It Matters
The 24% weight loss figure from the Phase 2 trial is genuinely unprecedented in pharmacology. For context, semaglutide (Wegovy) produces about 15% weight loss, and tirzepatide about 20%. Retatrutide's triple-receptor mechanism may represent the next generation of metabolic therapeutics. It's currently in Phase 3 trials, meaning it could reach clinical approval within the next few years.
The Bottom Line
Retatrutide is arguably the most scientifically exciting compound in this entire catalog right now. Its Phase 2 NEJM data showing 24% weight loss is unprecedented, and its triple-receptor mechanism is at the cutting edge of metabolic research. It is an investigational compound with no current regulatory approval, supplied for laboratory research use only.
Overview
What is Retatrutide?
Retatrutide (LY3437943, GLP-3 R) is a novel triple agonist developed by Eli Lilly that simultaneously activates three incretin and metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple agonism represents the next generation of metabolic peptide therapeutics, building on the success of GLP-1 agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide).
Phase II clinical trial data published in the New England Journal of Medicine (2023) demonstrated that retatrutide produced up to 24.2% mean body weight reduction at 48 weeks — the largest weight loss observed for any pharmacological agent in a clinical trial to date, surpassing even tirzepatide's results.
Key Takeaways
- Retatrutide (LY3437943) is a triple agonist simultaneously activating GLP-1R (appetite suppression, insulin secretion), GIPR (enhanced insulin sensitivity), and GCGR (thermogenesis, hepatic fat oxidation).
- Phase 2 NEJM trial (Jastreboff et al., 2023) demonstrated 24.2% mean body weight reduction at 48 weeks — the largest weight loss reported for any pharmacological agent in a randomized controlled trial.
- GCGR agonism is the distinguishing feature vs tirzepatide (GLP-1R/GIPR dual agonist): glucagon receptor activation increases brown adipose thermogenesis and hepatic fatty acid oxidation.
- Currently in Phase 3 TRIUMPH trials (obesity, T2D, cardiovascular outcomes); no regulatory approval in any jurisdiction as of 2026.
- For comparison: semaglutide 2.4 mg (STEP-1) = 14.9% weight loss; tirzepatide 15 mg (SURMOUNT-1) = 22.5%; retatrutide 12 mg (Phase 2) = 24.2%.
Composition
Molecular Composition
Amino Acid Sequence
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Lys(C20 diacid via linker)-Ala-Gln-Ala-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (39 AA, lipidated)
Retatrutide is a 37-amino-acid peptide with a fatty acid modification that enables once-weekly subcutaneous dosing through albumin binding. The sequence is based on a glucagon backbone with modifications that enable simultaneous engagement of GIPR, GLP-1R, and GCGR. The molecular weight is 4,731.33 Daltons.
The triple receptor agonism is achieved through careful sequence engineering: the N-terminal region is optimized for GLP-1R and GCGR engagement, while specific residues in the mid-sequence region enable GIPR activation. The fatty acid modification (C18 fatty diacid) enables albumin binding for extended half-life.
Mechanism of Action
How Does It Work?
!
Retatrutide drives the most potent weight loss observed in clinical trials by activating three receptors — GLP-1, GIP, and glucagon — simultaneously.
Retatrutide's mechanism of action involves simultaneous activation of three receptors with complementary metabolic effects. GLP-1R activation provides glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression. GIPR activation enhances insulin secretion and may contribute to the superior weight loss observed with dual/triple agonists compared to GLP-1R agonists alone.
GCGR activation is the distinguishing feature of retatrutide: glucagon receptor stimulation increases hepatic glucose production (which is counterbalanced by the GLP-1R-mediated insulin secretion), but more importantly, it increases energy expenditure through thermogenic effects in brown adipose tissue and hepatic fatty acid oxidation. This energy expenditure-increasing component may explain the superior weight loss efficacy of retatrutide compared to GLP-1/GIP dual agonists.
"Retatrutide's multifaceted mechanism of action, engaging GIP, GLP-1, and glucagon receptors, offers a promising therapeutic avenue for significant weight reduction and metabolic improvement, with Phase II data suggesting efficacy exceeding any previously studied pharmacological agent." — Jastreboff et al., New England Journal of Medicine, 2023
Signaling Pathways
Key Research Pathways
GLP-1R Signaling
Glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression via hypothalamic GLP-1R.
GIPR Signaling
Enhances insulin secretion and may contribute to superior weight loss vs. GLP-1R agonists alone through complementary beta cell effects.
GCGR / Energy Expenditure
Glucagon receptor activation increases hepatic fatty acid oxidation and brown adipose thermogenesis, raising total energy expenditure.
Albumin Binding (Fatty Acid Modification)
C18 fatty diacid modification enables reversible albumin binding, extending half-life to support once-weekly dosing.
Research Highlights
Key Findings from the Literature
- Up to 24.2% mean body weight reduction at 48 weeks in Phase II trial (Jastreboff et al., NEJM 2023)
- Triple agonism: GIPR + GLP-1R + GCGR — broadest incretin receptor coverage of any approved/investigational agent
- GCGR activation increases energy expenditure via brown adipose thermogenesis and hepatic FAO
- Significant reductions in HbA1c and fasting glucose in subjects with type 2 diabetes
- Once-weekly dosing enabled by C18 fatty diacid modification for albumin binding
- Currently in Phase III clinical trials (TRIUMPH program) as of 2025
Outcome Matrix
Evidence by Claimed Outcome
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
StrongModeratePreliminaryPreclinicalTheoretical
Claimed Outcome
Evidence Tier
Studies
Key Evidence Note
Weight reduction (≥20% body weight)
Moderate
2
Phase II trial (n=338): 24.2% mean weight loss at 48 weeks
Triple receptor agonism (GIP/GLP-1/GCG)
Moderate
3
Mechanism confirmed in Phase I/II; superior weight loss vs. dual agonists
Glycemic control
Moderate
2
Phase II data; not yet Phase III powered
Cardiovascular outcomes
Theoretical
0
Phase III trials not yet completed
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Evidence Database
Structured Evidence Table
1 cited study — model, sample size, outcome, and effect size from published literature.
| Study | Model | Sample | Outcome | Effect Size | Level |
|---|---|---|---|---|---|
Jastreboff AM, et al. (2023) Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial PubMed | Human — Phase II RCT | n=338 | 24.2% mean body weight reduction at 48 weeks (highest dose cohort) | 24.2% weight loss vs. 2.1% placebo; statistically significant (p<0.001) | Phase II |
Jastreboff AM, et al. (2023)
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Model
Human — Phase II RCT
Sample
n=338
Effect Size
24.2% weight loss vs. 2.1% placebo; statistically significant (p<0.001)
Evidence levels:RCTPhase IIIPhase IIObservationalAnimalIn Vitro
Evidence table is for educational reference only. Most peptide research is preclinical. Human RCT data is limited for most compounds. All compounds are for research purposes only — not for human use.
How Long It Lasts & How It Works in the Body
Retatrutide — half-life, bioavailability, onset, and duration data
Subcutaneous (SC)
| Parameter | Value | Source |
|---|---|---|
| Half-Life (t½) | ~6 days (144 hours) Range: 120–168 hours Phase 2 data; enables once-weekly dosing | Clinical Trial Data |
| Time to Peak (Tmax) | ~24–48 hours Phase 2 pharmacokinetic data | Clinical Trial Data |
| Bioavailability (F) | ~85% (estimated) Based on Phase 2 data; not yet in prescribing information | Clinical Trial Data |
| Protein Binding | >99% Fatty acid-mediated albumin binding | Clinical Trial Data |
| Onset of Action | 1–2 weeks Phase 2 NEJM data | — |
| Duration of Action | 7 days per dose | — |
Triple agonist (GLP-1/GIP/glucagon). Phase 2 data only as of 2025. PK profile similar to tirzepatide. Phase 3 TRIUMPH trials ongoing.
References:
• Jastreboff AM et al. NEJM 2023; 389:514-526 (TRIUMPH Phase 2)
Researcher Notes
Important Research Context
Status as of 9 October 2026: all four Phase 3 TRIUMPH trials have reported positive results and Lilly plans to file a Biologics License Application with the FDA in Q1 2027. Retatrutide is not approved for any indication and no application has been filed. "GLP-3 R" (also GLP-3 RT, RETA) is the name research-chemical vendors use for a product labelled retatrutide, sold for laboratory use only; it is not Lilly's drug and the trial results below describe Lilly's investigational product, not any vial sold under this name.
Phase 2 (Jastreboff et al., NEJM 2023, n=338): 12 mg −17.5% at 24 weeks and −24.2% at 48 weeks vs −2.1% placebo. Phase 3 TRIUMPH-1 (NCT05929066, n=2,339, topline 21 May 2026, published in NEJM): −28.3% at 80 weeks on 12 mg, −25.9% on 9 mg, −19.0% on 4 mg vs −2.2% placebo; 45.3% of the 12 mg arm lost ≥30%; discontinuation for adverse events 11.3% on 12 mg vs 4.9% placebo. TRIUMPH-2 (obesity with type 2 diabetes, 23 Jul 2026; full data at EASD 30 Sep 2026): up to −20.8%, A1C down up to 1.6 points. TRIUMPH-3 (BMI ≥35 with cardiovascular disease, 23 Jul 2026): up to −22.6%, pre-specified MACE-5 hazard ratio 0.82. TRIUMPH-4 (obesity with knee osteoarthritis, Dec 2025): −28.7% at 68 weeks.
Research References
Peer-reviewed literature supporting the research profile of Retatrutide
The following peer-reviewed studies form the primary evidence base for Retatrutide's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023.PMID: 37366315
Retatrutide achieved up to 24.2% body weight reduction at 48 weeks — the highest reported for any pharmacological agent in Phase II.
- 2.
Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. 2022.PMID: 35985340
Preclinical characterization of retatrutide's triple receptor agonism and metabolic effects.
Research Databases
Retatrutide
Metabolic Research
From $59.99
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
1 vial (10mg)
List price · read 12 Sep 2026
$59.99
1 vial (15mg)
List price
$84.99
1 vial (20mg)
List price
$119.99
1 vial (30mg)
List price
$159.99
10mg $59.99 → $47.99 with code HEALTH (20% off; price read 1 Nov 2026)
Where to buy Retatrutide
13 partners · prices read from product pages, latest 1 Nov · ranked by rubric, then price
- 1 certificate verified at the lab10mg$59.99→ $47.99
- 2 certificates verified at the lab10mg$699.99$80.00→ $64.00
- 1 certificate verified at the lab10mg$89.99$53.99→ $48.59
Every order also needs bacteriostatic water — add it to the same cart.All Retatrutide vendors, partners and not
Fast FedEx shipping · Discreet packaging
Sourced from Purgo Labs
✅≥99% Purity
📋COA Verified
🏭cGMP Made
Technical Specifications
- Peptide Class
- Triple incretin receptor agonist (37 amino acids)
- Molecular Weight
- 4,731.33 Da
- Receptor Targets
- GIPR + GLP-1R + GCGR (triple agonism)
- Clinical Stage
- Phase III (TRIUMPH program, 2025)
- Peak Weight Loss (Ph. II)
- Up to 24.2% at 48 weeks
- Available Sizes
- 5mg vials
- Form
- Lyophilized powder
- Purity
- ≥99% (third-party tested)
Legal Status
Research Chemical
View full legal status guide →
Known Interactions
5 documented interactions for Retatrutide
SemaglutideAvoid
Both target GLP-1 receptors. Combining is contraindicated due to additive receptor agonism and adverse event risk.
Clinical evidence
IGF-1 LR3Caution
Both affect glucose metabolism. Monitor blood glucose if combining.
Theoretical evidence
BPC-157Neutral
BPC-157 may support GI health during triple agonist therapy. No known negative interaction.
Theoretical evidence
Interaction data is based on published research, known pharmacological mechanisms, and clinical practitioner experience. Evidence tiers: Clinical = human data; Emerging = preclinical/case reports; Theoretical = mechanism-based inference. Always consult a qualified healthcare provider before combining compounds.
Interaction Guides
Source Retatrutide at Purgo Labs
10mg $59.99 list · $47.99 with code HEALTH · lab-verifiable COA per lot
Vendor Scoreboard — top 3 by verified evidenceVerified 1 November 2026
Related Research
Other Compounds in This Guide
Vendor codes
Also sold as: what vendors call retatrutide
Since the 2025–26 enforcement wave almost no vendor lists retatrutide by name. These are the 39 house codes we have read on vendor pages. 24 of them come with a stated identity (a CAS number, a lab lot prefix on the vendor's certificate page, or the vendor's own FAQ); the rest are codes only, and we keep those out of the price table.
AMP-3 (RT)Amino Club'Reta (GLP-1/GIP/GCG) 10mg'Blue Sky Peptide'Triple Agonist'Crush ResearchGLP-3 RTDisguised AlphaElite-3RTElite Edge BiotechGLP-3 (R)Evo Labs Research'GLP-3-RT'ezPepsGLP-3 RHonest PeptideGLP-3 RTIdun Peptides'GLP 3 (RT)'Kylo PeptidesGLP3-ROath ResearchOC-3RT (GLP3-R)Oneday CompoundsOPTI-(R)Optima Supply'Triple Receptor Agonist'Panda Peptides'GLP-3'Peak Lab PeptidesRT-3Peptide Giants'GLP-3 Retatrutide'Peptide PartnersPBL-RT3Premier Bio LabsGLP/GIP/GLC-RtProfound AminosGLP-3 RPurgo LabsRIVN-3RTRivn PeptidesGLP-3RetaValidated PeptidesVRC-3RValor Peptides'VRL-3 (RT)'Value Research LabsGLP-3 AL (R)Accelerate LabsGLP3-RAIO PeptidesAMP-3PAmeano PeptidesAL-3RTAmplified LabsBRP-3RBlue Ridge PeptidesEZP-3PEZ PeptidesFG3-RGlow AminosLP3-RLicensed PeptidesMA-3RTModern AminosPS-R3Petratide SciencePUR-3RPuratek PeptidesSP-R3Snap PeptidesZC-RTZC LabsRPP3-RRamp PeptidesORP-3ROptimum Regen Peptides
Full decoder: every GLP-1, tirzepatide and retatrutide vendor code, with the evidence behind each · green = identity stated, amber = code only
Safety
Retatrutide side effects
Human trial dataPhase 2 human trial data exist; not approved anywhere — figures are from the phase 2 obesity trial
Retatrutide is unapproved and still in phase 3, so its safety profile is provisional. The phase 2 obesity trial reported dose-dependent gastrointestinal effects during escalation, discontinuations that rose with dose, and an increase in heart rate. Long-term safety is unknown.
Research-use information only. Research-grade Retatrutide is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This section does not give dosing or medical advice.
What is reported
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Gastrointestinal events (nausea, diarrhoea, vomiting, constipation) | not quantified | Dose-related, mostly mild-to-moderate, concentrated during escalation. | Jastreboff et al. 2023 (phase 2) |
| Discontinuation for adverse events | 6–16% across dose groups vs 0% placebo | Higher at higher doses. | Jastreboff et al. 2023 |
| Heart-rate increase | not quantified | Dose-dependent rise observed, greatest early in treatment. | Jastreboff et al. 2023 |
| Dysaesthesia / skin sensitivity | not quantified | Reported in the phase 2 programme at higher doses. | Jastreboff et al. 2023 |
What is not known
- •Everything beyond 48 weeks.
- •Cardiovascular outcomes (phase 3 ongoing).
- •Identity and dose of research-grade material — several vendors sell it under house codes without a CAS number.
Mechanism-based cautions
- •Assume GLP-1 class warnings apply until shown otherwise.
- •Glucagon-receptor activity adds a mechanism (hepatic glucose output, heart rate) the dual agonists do not have.
Regulatory status: Not approved anywhere; Eli Lilly phase 3 (TRIUMPH) ongoing as of 2026.
Side-effect references
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023. PMID 37366315.
What is actually in a research vial
Everything above describes Retatrutide the molecule. The risk specific to a research vial is different: it may not contain Retatrutide at the labelled amount, and it may contain what the synthesis left behind. Identity (mass spectrometry), purity (HPLC), measured net content and an endotoxin result are the four lines on a certificate that bear on adverse effects, and only a certificate you can check at the laboratory tells you any of them. This is what we have verified for Retatrutide so far.
Who sells Retatrutide, and what they document
28 of the 105 vendors on our scoreboard list Retatrutide with a price we read on the product page (5 Sep 2026–1 Nov 2026). Of those, 27 name their testing laboratory, 24 publish certificates that resolve on the lab's own site, and 27 publish measured milligrams against the label. The full ranking, with every dated price, is on Best Retatrutide Vendors.
| Vendor | Rubric | Lab named | Price read |
|---|---|---|---|
| Idun Peptides | 10/10 | Kovera Labs (named in certificate captions only) | $44.99 · 10mg · 5 Sep 2026 |
| MyPurePeptidepartner | 10/10 | Janoshik Analytical | $80.00 · 10mg · 1 Nov 2026 |
| Oneday Compoundspartner | 10/10 | ILS Laboratories (San Diego, CA) | $32.99 · 5mg · 29 Oct 2026 |
| Panda Peptides | 10/10 | Janoshik Analytical · ILS Labs (per batch) | $53.99 · 10mg · 25 Oct 2026 |
| Peptide Giantspartner | 10/10 | Janoshik Analytical · Vanguard Laboratory | $39.99 · 5mg · 1 Nov 2026 |
Top 5 by rubric score; 23 more on the ranking page.
Retatrutide certificates we have opened
4 certificates for Retatrutide in the COA library: 4 checkable on the laboratory's own site, 4 stating measured mass against the label, 2 carrying a flag.
- Oneday Compounds· 10mg · lot OC-RT10-106 · ILS Labs COA-2026-3WBETH (access code YX3QRWQ5)· 99.63% purity· 104% of labelverify at ILS Labs
- Peptide Partners· 24mg · lot RT2622 · TrustPointe Analytics SPL-4920 (key PNK34NHNGMLK)· 99.9% purity· 100% of labelverify at TrustPointe Analytics
- Kylo Peptides· 10mg · lot SD-260728-1 · Freedom Diagnostics 2608170152 (search code KYLO2608170152)· 99.87% purity· 113% of labelverify at Freedom Diagnostics One vial measured
- Peak Lab Peptides· 10mg · lot RT-202602-001 at the lab; RT-202607-001 on the vendor's copy · Bioviridian COA6671· 99.7% purity· 104% of labelverify at Bioviridian One vial measured
Side-effect questions
Side-effect section last reviewed 2026-09-12. Moved from the standalone side-effects page on 10 October 2026; text unchanged.
Regulatory
Is Retatrutide legal?
Legal as a research chemical (Phase 3 trial)Retatrutide is not yet FDA-approved and is currently in Phase 3 clinical trials as of 2025. It is available as a research chemical for laboratory research purposes. It is not a controlled substance.
US Status
Research Chemical
Legal to purchase for research
DEA Schedule
Not Scheduled
Not a controlled substance
FDA Status
Not Approved
Not FDA-approved — currently in Phase 3 clinical trials
Status by country
| Jurisdiction | Status as stated |
|---|---|
| United States | Not FDA-approved. Currently in Phase 3 clinical trials. Available as a research chemical for laboratory research. Not a controlled substance. |
| Canada | Not approved by Health Canada. Available for research purposes. |
| United Kingdom | Not licensed by the MHRA. Available for research purposes. |
| Australia | Not approved by the TGA. Available for research purposes. |
| European Union | Not approved by the EMA. Available for research purposes. |
Statements above are as our legal-status page for Retatrutide stated them in 2025; they were moved here on 10 October 2026 and were not re-verified in the move. Regulations change. This is general information, not legal advice; check the current position with your own jurisdiction's regulator before relying on it.
Legal questions
Is retatrutide FDA-approved?
No. As of 2025, retatrutide is in Phase 3 clinical trials and has not yet received FDA approval. It is available as a research chemical for laboratory research purposes only.
Is retatrutide a controlled substance?
No. Retatrutide is not listed as a controlled substance under the DEA Controlled Substances Act.
When will retatrutide be FDA-approved?
Based on Phase 3 trial timelines, retatrutide could potentially receive FDA approval in 2026 or 2027, though this timeline is not guaranteed.
Is retatrutide legal to buy?
Yes. Retatrutide can be legally purchased as a research chemical in the United States for legitimate laboratory research purposes.
How does retatrutide differ from tirzepatide legally?
Tirzepatide is FDA-approved (as Mounjaro and Zepbound), while retatrutide is still in clinical trials. Both are available as research chemicals, but tirzepatide also has an approved prescription form.
Research Guides
Related Research Guides
Everything we publish on Retatrutide
More on Retatrutide: comparisons, interactions, where to buy
- Eli Lilly's Retatrutide Lawsuits (2026): Six Sellers Sued — What It Means for Buyers
- Retatrutide (RETA / GLP-3 R) Guide — Mechanism, Phase 3 TRIUMPH Results & Status (October 2026)
- Retatrutide Before and After: Real Results & Timeline (2026)
- Retatrutide Clinical Trials (October 2026): Phase 3 TRIUMPH Results, Phase 2 Data & FDA Timeline
- Retatrutide FDA Approval Status (October 2026): Not Approved — BLA Filing Q1 2027, Decision 2027–2028
- Retatrutide for Type 2 Diabetes: Triple Mechanism, Phase 2 Data & Dosing (2026)
- Retatrutide for PCOS: Triple Receptor Advantage & Results (2026)
- Retatrutide Phase 3 Results (October 2026): All Four TRIUMPH Trials Reported, BLA Filing Q1 2027
- Retatrutide Phase 3 Results (October 2026): TRIUMPH-1 −28.3%, All Four Trials Reported, BLA Q1 2027
- Tirzepatide vs Retatrutide: Weight Loss, Mechanism & Clinical Data (2026)
- Retatrutide and Alcohol — Interaction Research Guide
- Retatrutide and Metformin — Interaction Research Guide
- Retatrutide vs Ozempic — Research Comparison
- Retatrutide vs Tirzepatide — Research Comparison
- Semaglutide vs Tirzepatide vs Retatrutide — Research Comparison
Supporting Research
Phase 2 Human TrialPhase 2 human RCT — Phase 3 ongoing, not yet approved
Evidence note: Retatrutide is an investigational compound. Phase 3 trials are ongoing. It has not received regulatory approval in any jurisdiction as of 2026.
Retatrutide has Phase 2 human trial data showing exceptional weight loss (24.2% at 48 weeks). Phase 3 is ongoing. It is investigational — not FDA-approved. Claims about weight loss efficacy can be stated with confidence when tied to the Phase 2 NEJM trial, but must be accompanied by the Phase 3 / not-approved caveat.
References
- Jastreboff AM, et al.[HUMAN Phase 2 RCT, n=338]Up to 24.2% mean body weight reduction at 48 weeks — highest reported for any pharmacological agent in a Phase 2 trial.
- Coskun T, et al.[PRECLINICAL + early human PK]Triple receptor agonism characterization; GIP/GLP-1/GCGR co-agonism mechanism.
Research Databases
PubMedNCBIClinicalTrials.gov
Ready to Source Retatrutide?
Purgo Labs offers Retatrutide with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.